Cantourage Group SE: Most potent cannabis flower on the German market: Cantourage launches Miracle Valley’s second product

EQS-News: Cantourage Group SE

/ Key word(s): Product Launch/Market Launch

Cantourage Group SE: Most potent cannabis flower on the German market: Cantourage launches Miracle Valley’s second product
14.12.2022 / 13:08 CET/CEST

The issuer is solely responsible for the content of this announcement.

Not for release or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction where such release or distribution would be unlawful. Please see the important notice at the end of this announcement.

Most potent cannabis flower on the German market: Cantourage launches Miracle Valley’s second product

 

  • Cantourage continues to spearhead innovation in the European cannabis industry by introducing the Ice & Sugar cultivar – now available in pharmacies throughout Germany for the first time
  • First batch of product has the highest THC concentration of any medical cannabis flower released in Germany to date, opening up an additional treatment option for patients with high THC demand
  • Flowers are cultivated by Miracle Valley in Canada with a “craft growing” approach – a category in which Cantourage plans to add more products in the coming months
 

Berlin, 14 December 2022 – Cantourage Group SE (FRA:HIGH), a European medical cannabis leader, and Miracle Valley, a Canada-based cannabis grower, have extended their partnership for patients across Germany to have an even larger variety of high THC medical cannabis products at their disposal. After successfully introducing Miracle Valley’s highly sought-after Mac 1 cultivar to the German market in April 2022, patients throughout Germany now have access to Miracle Valley’s second cultivar on the German market, Ice & Sugar. Both flowers are cultivated under “craft growing” conditions in British Columbia, Canada. Ice & Sugar’s first batch has the highest THC content of any medical cannabis flower released in Germany to date.

Earlier this year, right after disrupting the Dronabinol (neat THC) market with its Dronabinol solution, Cantourage launched Miracle Valley’s Mac 1, which at the time set a new gold standard for medical cannabis quality in Germany. Miracle Valley cultivates medical cannabis in a distinctive “craft growing” approach, allowing for small batches of high-quality medical cannabis grown in a controlled indoor environment. Through its unique sourcing network and its own manufacturing platform, Cantourage plans to further extend its supply within the “craft cannabis” segment in early 2023 in order to meet the rapidly increasing demand for premium quality medical cannabis flowers by patients in Germany and other European countries.

Sebastian Blöte, European Sales Director of Cantourage, commented: “We are excited to set yet another benchmark in our industry by adding Miracle Valley’s Ice & Sugar cultivar to our medical portfolio, continuing our efforts to provide patients in Europe with the best cannabis from around the world. Mac 1 has already set new quality standards on which we now build with Miracle Valley’s second product.”

Scott Mayer, CEO of Miracle Valley, added: “At Miracle Valley, we are all about setting new standards for premium cannabis cultivation and to provide patients with the highest quality cannabis strains available. We are pleased that by expanding our cooperation with Cantourage, another of our high-quality products will now be available in Europe.”

Miracle Valley is a fully operational facility licensed under the Cannabis Act of Canada and based in British Columbia in the Cascade Mountain Range. As a privately held company founded in July 2013, Miracle Valley has made its mission to serve the needs of customers and patients alike, while setting new quality benchmarks for medical cannabis flowers.
Cantourage processes the cannabis flowers, transforming them to medical cannabis products, and makes them available to pharmacies in Germany, the EU and UK.

—END—

About Cantourage
Cantourage is a publicly listed, leading European medical cannabis company. The Berlin-based company with subsidiaries in the United Kingdom and Poland, was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. Cantourage enables producers from all over the world to become part of the rapidly growing European medical cannabis market in a faster and more cost-effective way, while guaranteeing and developing the highest European quality standards. The company offers products in all relevant market segments: dried flowers, extracts, Dronabinol and pharma-grade Cannabidiol. The company was listed on the Frankfurt Stock Exchange on 11 November 2022 and is listed under the stock ticker “HIGH”.

About Miracle Valley
Miracle Valley is an uncompromising, cultivation focused-premium flower company, dedicated to the art and science of growing the best cannabis plants in Canada. As a privately held company, Miracle Valley is dedicated to the customer as its shareholders – not the public markets. Miracle valley is led by cannabis enthusiast Scott Mayer. Miracle Valley’s strength and passion are cannabis flowers. Its vision is to raise the standard in the premium cannabis flower category by providing unique and exotic genetics expertly grown by passionate people.

Press contact
Kekst CNC
cantourage@kekst.com 
Roland Leithäuser
+49 162 2074592

This announcement does not constitute a public offer or an advertisement for a public offer within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).
This announcement is not an offer of securities for sale in the United States of America. Securities may not be sold or offered in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”). Any public offering of securities to be made in the United States would be made by means of a prospectus that could be obtained from the Company. This prospectus would contain detailed information about the Company and its management, as well as the Company’s financial information. There will be no public offering of the securities referred to in this announcement in the United States of America.
In the United Kingdom, this information may only be communicated to and is only directed at (i) professional investors within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), or (ii) high net worth companies falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to herein as “Relevant Persons”). The Securities are only available to Relevant Persons and any invitation, offer or agreement to subscribe for, purchase or otherwise acquire such Securities will only be engaged in with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this announcement or any of its contents.
Subject to certain exceptions, the securities referred to in this announcement may not be sold or offered in Australia, Canada or Japan, or to or for the account or benefit of any national, resident or citizen of Australia, Canada or Japan
 

 


14.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


show this